top of page
  • Active, not recruiting

NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Updated: Feb 10

  • EMN26

  • NCT04564703: Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients


iberdomide maintenance

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients


This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenance treatment after transplant.


Sponsor


Collaborators

Celgene Corporation

Healt Data Specialists - HeaDS (CRO)

EMN Research Italy Impresa Sociale Srl


Location

Europe

 

ClinicalTrials.gov Identifier: NCT04564703


Official Title: Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients


First Posted: September 25, 2020


Click here for details on Clinicaltrials.gov


 

Drug: Iberdomide

 

Locations

Europe

France

Greece

Italy

Netherlands







Commentaires


Les commentaires ont été désactivés.
Posts Archive
bottom of page